BeiGene (BGNE) Commences Pivotal Trial of PD-1 Antibody BGB-A317 in China in Patients with Urothelial Cancer

July 5, 2017 7:03 AM EDT Send to a Friend
BeiGene, Ltd. (NASDAQ: BGNE) today announced that the first patient was dosed in a pivotal clinical trial in China of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login